GSK BEGINS TRIAL OF ELTROMBOPAG

GlaxoSmithKline (GSK) has initiated a Phase III study of eltrombopag for treatment of idiopathic thrombocytopenic purpura, or low platelet counts.

The study, which will take place at trial sites in 33 countries, will involve patients with ITP who have not responded to previous treatments or relapsed. Study participants will be randomized to receive either eltrombopag or placebo for six weeks.